Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STC314 Injection in ARDS
NCT05000671Phase 1Unknown
- Sponsor
- Grand Medical Group AG
- Start
- Jul 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of STC3141 in acute respiratory distress syndrome (ARDS) (3 arms), sponsored by Grand Medical Group AG. Primary endpoints: Safety of STC314 injection at 28 days and Pharmacokinetics of STC314 injection. Status: unknown.
02
Drugs
STC3141
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05000671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05000671.